JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management
United European Gastroenterology Journal · 2025-05 · 13 (4) · 505-507
DOI: 10.1002/ueg2.12716 ↗Kurz gefasst
Editorial in der Zeitschrift United European Gastroenterology Journal, online erschienen am 29.11.2024. Verfasst von Luisa Bertin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Azienda Ospedale Università Padova, Padova, Italy. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Inflammatory Bowel Diseases, Intestinal Perforation, Janus Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
JAK inhibitors are pivotal in treating immune‐mediated inflammatory diseases (IMIDs) like rheumatoid arthritis (RA) and inflammatory bowel disease. However, emerging safety concerns warrant careful evaluation. A recent analysis of the FDA Adverse Event Reporting System (FAERS) revealed that RA patients using JAK inhibitors face nearly double the risk of gastrointestinal perforations (GIPs) compared to those on biologics, particularly with concurrent steroid or NSAID use. Additionally, the FDA's ORAL Surveillance study linked tofacitinib with higher rates of cancer and cardiovascular events, prompting regulatory restrictions. These findings highlight the importance of balancing JAK inhibitors' therapeutic benefits with potential risks, emphasizing the need for patient‐centred risk assessment and vigilant monitoring to optimize outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Unit, Azienda Ospedale Università Padova, Padova, Italy.
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
- Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
ORCID-Profile: Luisa Bertin
Zitieren
APA
Bertin, L., & Savarino, E. V. (2025). JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management. United European Gastroenterology Journal, 13(4), 505-507. https://doi.org/10.1002/ueg2.12716
Vancouver
Bertin L, Savarino EV. JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management. United European Gastroenterology Journal. 2025;13(4):505-507. doi:10.1002/ueg2.12716
BibTeX
@article{Bertin2025,
author = {Bertin, Luisa and Savarino, Edoardo Vincenzo},
title = {JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management},
journal = {United European Gastroenterology Journal},
year = {2025},
volume = {13},
number = {4},
pages = {505--507},
doi = {10.1002/ueg2.12716}
}
EUVIMED